Treatment with R-bendamustine followed by Y-90 ibritumomab tiuxetan for relapsed/refractory low-grade B-cell lymphoma

被引：0
|
作者：
Nikkuni, Koji [1 ]
Abe, Takashi [1 ]
Takai, Kazue [1 ]
机构：
[1] Niigata City Gen Hosp, Niigata, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O1-13-5
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
    Witzig, TE
    Gordon, LI
    Cabanillas, F
    Czuczman, MS
    Emmanouilides, C
    Joyce, R
    Pohlman, BL
    Bartlett, NL
    Wiseman, GA
    Padre, N
    Grillo-López, AJ
    Multani, P
    White, CA
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (10) : 2453 - 2463
  • [42] Yttrium-90 (Ytracis) Labelled Ibritumomab Tiuxetan (Zevalin) in Patients with Relapsed or Refractory B-Cell non-Hodkin's Lymphoma
    Lipp, R. W.
    Piswanger-Soelkner, J. C.
    Dorda, A. F.
    Brezinschek, R. I.
    Lackner, H.
    Linkesch, W.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S93 - S93
  • [43] Factors associated with effects of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma: single-institution experience with 94 Japanese patients in rituximab era
    Naokuni Uike
    Ilseung Choi
    Mariko Tsuda
    Shojirou Haji
    Kousuke Toyoda
    Youko Suehiro
    Yasunobu Abe
    Toshinobu Hayashi
    Hirofumi Sawamoto
    Koichiro Kaneko
    Mototsugu Shimokawa
    Makoto Nakagawa
    International Journal of Hematology, 2014, 100 : 386 - 392
  • [44] Factors associated with effects of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma: single-institution experience with 94 Japanese patients in rituximab era
    Uike, Naokuni
    Choi, Ilseung
    Tsuda, Mariko
    Haji, Shojirou
    Toyoda, Kousuke
    Suehiro, Youko
    Abe, Yasunobu
    Hayashi, Toshinobu
    Sawamoto, Hirofumi
    Kaneko, Koichiro
    Shimokawa, Mototsugu
    Nakagawa, Makoto
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2014, 100 (04) : 386 - 392
  • [45] A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma
    Beaven, Anne W.
    Shea, Thomas C.
    Moore, Dominic T.
    Feldman, Tatyana
    Ivanova, Anastasia
    Ferraro, Madlyn
    Ford, Peggy
    Smith, Judith
    Goy, Andre
    LEUKEMIA & LYMPHOMA, 2012, 53 (02) : 254 - 258
  • [46] 90Y-IBRITUMOMAB TIUXETAN TREATMENT FOR RELAPSED AND/OR REFRACTORY B CELL NON-HODGKIN'S LYMPHOMA. MULTI-INSTITUTIONAL ARGENTINIAN STUDY
    Cacchione, R.
    Milone, J.
    Nucifora, E.
    Bordone, J.
    Dupont, J.
    Rudoy, S.
    Brown, M.
    Lafalce, D.
    Palmer, L.
    Argentieri, D.
    Negri, P.
    Bartomioli, M.
    Milone, G.
    Trouboul, A.
    Ardaiz, M.
    Iabstrebner, M.
    Pombo, G.
    Basso, A.
    Diaz, A.
    Tur, R.
    Saidon, G.
    Krupitzki, H.
    Garay, G.
    Riveros, D.
    Carrasco, A.
    Chiattone, C.
    Bezares, E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 109 - 109
  • [47] TREATMENT WITH YTTRIUM-90 (90Y)-IBRITUMOMAB TIUXETAN (ZEVALIN®) IN DIFFUSE LARGE B-CELL LYMPHOMA: A META-ANALYSIS
    Auger, S.
    Duny, Y.
    Daures, J. P.
    Quittet, P.
    HAEMATOLOGICA, 2014, 99 : 700 - 700
  • [48] 90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease
    Samaniego, Felipe
    Berkova, Zuzana
    Romaguera, Jorge E.
    Fowler, Nathan
    Fanale, Michelle A.
    Pro, Barbara
    Shah, Jatin J.
    McLaughlin, Peter
    Sehgal, Lalit
    Selvaraj, Vijairam
    Braun, Frank K.
    Mathur, Rohit
    Feng, Lei
    Neelapu, Sattva S.
    Kwak, Larry W.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 167 (02) : 207 - 213
  • [49] Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine
    Isono, Noriko
    Imai, Yoichi
    Watanabe, Aya
    Moriya, Keiichi
    Tamura, Hideto
    Inokuchi, Koiti
    Asano, Chihiro
    Masuda, Michihiko
    Shimura, Hanae
    Mitsuhashi, Kenjiro
    Kazama, Hiroshi
    Sugimori, Hiroki
    Motoji, Toshiko
    Tanaka, Junji
    LEUKEMIA & LYMPHOMA, 2016, 57 (09) : 2204 - 2207
  • [50] Yttrium-90 Ibritumomab Tiuxetan is Cost-Effective Compared to Bendamustine plus Rituximab in Low-grade Lymphomas
    Moustafa, Muhamad Alhaj
    Borah, Bijan J.
    Moriarty, James P.
    Dholakia, Ruchita
    Jiang, Liuyan
    Li, Ke
    Witzig, Thomas E.
    Hoppe, Bradford S.
    Peterson, Jennifer
    Cerhan, James R.
    Tun, Han W.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (04): : 259 - 265
12345